CSF2 and melanoma: A groundbreaking advancement in this field was the U.S. Food and Drug Administration (FDA) approval of T-VEC (Talimogene) in 2015, an HSV-1-based oncolytic virus armed with GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor), for the treatment of melanoma (225).